Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. by Secreto, G. et al.
Br. J. Cancer (1983), 47, 269-275
Circulating levels of testosterone, 17fl-oestradiol, luteinising
hormone and prolactin in postmenopausal breast cancer
patients
G. Secreto, C. Recchione, A. Cavalleri, M. Miraglia & V. Dati
Hormone Research Laboratory, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Summary Serum testosterone, 17f-oestradiol, luteinising hormone (LH) and prolactin were measured in 28
postmenopausal breast cancer patients after mastectomy and in 30 postmenopausal normal controls. In the
patient group, mean levels of oestradiol, LH and prolactin did not differ significantly from those of the
control group. Mean testosterone levels were higher in breast cancer patients than in normal controls, either
considering the overall groups (P<0.001) or dividing them into subgroups according to years since
menopause. Breast cancer patients were divided into 2 subgroups according to time since mastectomy: 19
patients had been examined within a year of mastectomy and 9 patients some years after mastectomy.
Testosterone, but not oestradiol, LH or prolactin values in each subgroup were still significantly higher
(P<0.001 and P<0.02, respectively) than in normal controls. Years since menopause were significantly
correlated with testosterone (r=0.533, P<0.01) but not with the other hormones in the cancer group. These
results confirm our previous findings of increased urinary testosterone values in postmenopausal breast cancer
patients and support the hypothesis that androgens may play a role in the development of breast cancer.
Sex hormones and possibly prolactin may play an
important role in the control of neoplastic growth
of breast cancer, but results of hormonal
determination have often been contradictory. Most
of the studies have found no significant increase in
the circulating levels of oestrogens and prolactin
(Nagasawa, 1979; Nisker & Siiteri, 1981; Zumoff,
1981) in breast cancer patients, and the few reports
of testosterone levels are conflicting, normal values
having been found by some authors (Bird et al.,
1981; Borkowski et al., 1977; Horn & Gordan,
1974) and increased levels by others (Adami et al.,
1979; McFadyen et al., 1976). Malarkey et al.
(1977) reported increased testosterone levels in
premenopausal and normal testosterone levels in
postmenopausal patients.
In the present work we report circulating levels
of testosterone, oestradiol, prolactin, and luteinising
hormone (LH) in postmenopausal breast cancer
patients and in normal controls. The finding of
increased testosterone levels in breast cancer
patients supports our previous findings based on
urine measurements (Grattarola et al., 1974, 1975).
Patients and methods
Breast cancer patients
Twenty-eight patients who had previously
Correspondence to: G. Secreto, Hormone Research
Laboratory, Istituto Nazionale Tumori, Via Venezian 1,
20133 Milano, Italy.
Received 8 June 1982; accepted 21 October 1982.
0007-0920/83/020269-07 $02.00
undergone mastectomy for infiltrating carcinoma of
the breast were studied. All of them were disease-
free at the time of hormonal examination. The age
of these patients was 47-77y (mean 58.5y) and all
had been postmenopausal for 1-28y. The patients
were divided into 3 subgroups according to years
since menopause: 10 patients were 1-5y
postmenopausal, 8 were 6-10y postmenopausal,
and 10 were >10y postmenopausal.
Twenty-five of the 28 patients married between
the age of 21 and 36 years and had had at least one
full-term pregnancy between the ages of 23 and 41
years. Three patients were single and had had no
pregnancy.
The patients were divided into 2 subgroups
according to the interval between mastectomy and
hormonal examination: 19 patients were examined
from 2-12mo since mastectomy and 9 patients were
examined from 2-17y since mastectomy.
No patient had been previously ovariectomized
and none had been treated with hormones or
chemotherapy for breast cancer. None of them had
been taking any hormonal drug for at least 6mo
before testing or digitalis, antihypertensive or
psychotropic drugs for chronic disease.
Control subjects
Thirty normal controls selected from healthy
women fulfilled the following criteria: (a) no
abnormality of the breast on clinical examination;
(b) no benign or malignant neoplasm elsewhere; (c)
no endocrine, metabolic or chronic disease; (d) no
family history of breast cancer; (e) no involuntary
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infertility; (f) no menstrual cycle irregularities in the
past.
Ages were 49-77y (mean 57.4y), and all had
been postmenopausal for 1-30y. They were divided
into 3 subgroups according to years since
menopause: 12 were 1-5y postmenopausal, 11 were
6-10y postmenopausal, and 7 were >10y
postmenopausal.
Twenty-four had married between the ages of 18
and 30y and delivered at least one full-term
newborn between the ages of 20 and 32y. Six
control subjects were single and had had no
pregnancy.
Table I reports the ranges and means for the
various characteristics of the patients and the
controls.
Methods
Hormonal determinations were performed on
peripheral blood samples drawn between 9a.m. and
11 a.m. Blood was allowed to clot at room
temperature, centrifuged and serum separated and
stored at -20°C until assayed. Testosterone,
oestradiol, LH and prolactin levels were determined
by radioimmunoassay in the same blood samples.
For the determination of testosterone,
preliminary chromatography was performed with a
Sephadex LH-20 column according to the method
of Collins et al. (1972). However, since we wished
to eliminate dihydrotestosterone we performed the
assay of testosterone only on the fraction of elution
between 0.9 and 2.0ml immediately after the
azobenzene.
The cross-reaction of the antibody towards
testosterone-3-oximebovine serum albumin, which
we used, was <0.1% for all the principal steroids,
except for dihydrotestosterone (17,B-hydroxy-5c-
androstan-2-one), 5-androsten-313-177f-diol, and 5a-
androstan-3a-17#-diol. These steroids were thus
eliminated by chromatography.
The separation of free testosterone from that
bound to the antibody was performed by use of the
double antibody method (Ismail et al., 1972). The
levels of testosterone found'by interpolation of the
standard curve were corrected for the recoveries
(which were from 50-70%), whereas no correction
was made for the blanks, since these were
negligible.
The levels of oestradiol were determined without
preliminary chromatography (Ricci & Sacconi,
1976), using a rabbit antibody raised against 17#-
oestradiol-6-carboxymethyloxime-bovine serum
albumin, which was highly specific (Ricci &
Sacconi, 1976), and polyethylene glycol for
separating bound from free steroid (Desbuquois &
Aurbach, 1971). LH and prolactin were respectively
determined with the methods of Midgley (1966) and
Sinha et al. (1973). LH was expressed in
international milliunits of the Second International
Reference Preparation of Human Menopausal
Gonadotropin (2nd IRP-HMG); prolactin in
nanograms of the National Institutes of Health
Standard (NIH Code Fl) (1 ng=23+3,uIU of
WHO 71/222).
Testosterone-3-tyrosine-methyl-ester, LH and
prolactin, labelled with 1125 with the method of
chloramine T (Greenwood et al., 1963), 2,4,6,7-
[3H]-17f1-oestradiol, and the respective antibodies
were supplied by Biodata (Milan, Italy).
The coefficients of intra- and inter-assay
variation were respectively 9.5% and 18.3% for
testosterone, 8% and 15% for oestradiol, 5.5% and
7% for LH, and 5.86% and 9% for prolactin.
Comparisons of hormone levels between cancer and
control groups and between their subgroups "time
since mastectomy" and "years since menopause"
were performed by Student's t-test, after conversion
of data to a logarithmic scale. The correlation
between the 4 hormones studied in the control
group and in the cancer group and the correlation
of each hormone with age at menopause and years
since menopause were analyzed by determining the
linear coefficient of correlation with the
corresponding P values. Two-tailed P values were
considered for all the statistical analyses.
Results
Mean age, mean age at menopause, mean time
since menopause to hormonal examination, and
mean age at marriage did not differ significantly
between normal controls and breast cancer patients.
Mean age at first pregnancy was signficiantly lower
in the control group (P<0.01) and mean number of
full-term pregnancies was significantly lower in the
breast cancer group (P<0.02) (Table I). Within the
breast cancer group, the subgroups 2-12mo since
mastectomy and >2y since mastectomy did not
differ significantly for age, age at menopause and
years since menopause.
Testosterone
The mean value in the breast cancer group was
0.554+0.2ngml-1 and in normal controls
0.318+0.llngml-1 (P<0.001) (Table II). The
distribution was shifted to higher values in the
patient group, where we found values exceeding
0.58 ngml1 (upper limit for normal controls) in 14
patients.
Time since mastectomy The mean testosterone
value in the 19 patients examined within 12mo of
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Table I Age, age at menopause, years since menopause to hormonal examination, age at marriage, age at first
term pregnancy and number of full-term pregnancies in normal postmenopausal controls and in postmenopausal
breast cancer patients (ranges and mean +s.d.)
Normal controls Breast cancer patients
No. No.
cases Range Mean+s.d. cases Range Mean+s.d. Significance
Age (y) 30 49-77 57.4+6.7 28 47-77 58.5+7.2 NS*
Age at menopause (y) 30 42-55 49.6+3.9 28 43-54 48.9+4.4 NS
Years since menopause (y) 30 1-30 7.8+7.1 28 1-28 9.9+8.0 NS
Age at marriage (y) 24 18-30 23.5+3.1 25 21-36 27.1 +4.5 NS
Age at first pregnancy (y) 24 20-32 25.1 +3.5 25 23-41 29.3+5.2 P<0.01
Number of pregnancies 24 1-6 2.6+ 1.5 25 1-3 1.7+0.8 P<0.02
*NS, not significant.
Table II Ranges and mean values of testosterone, 17,B-oestradiol, luteinising hormone (LH), and prolactin in
postmenopausal normal controls and in postmenopausal breast cancer patients
Normal controls Breast cancer patients
No. No.
cases Range Mean+s.d. cases Range Mean+s.d. Significance
Testosterone (ngmml) 30 0.12- 0.58 0.31+ 0.11 28 0.18- 0.99 0.55+ 0.2 P<0.001
Oestradiol (pgmlP) 30 15.50- 95.50 26.45+15.03 24 15.50- 62.00 24.27+ 10.38 NS*
LH (mIUml-') 30 35.20-192.50 94.73 +37.93 28 28.50-210.00 102.82+42.07 NS
Prolactin (ngml-1) 30 3.75- 26.50 7.79+ 4.78 28 4.60- 17.50 8.94+ 3.27 NS
*NS, not significant.
years after mastectomy, but the difference was not
statistically significant (Table III). In both these
subgroups the mean testosterone value was
significantly higher than in the control group
(P<0.001 and P<0.02, respectively).
Years since menopause In all 3 subgroups of
breast cancer patients, mean testosterone levels
were higher than in those of normal controls. The
difference was statistically significant in the
subgroups 1-5 (P<0.05) and > lOy since
menopause (P<0.001) (Table IV). Within the breast
cancer group, mean testosterone level significantly
increased in the subgroup > 1Oy since menopause
(P<0.O01). On the other hand, within the control
group, a decrease in mean testosterone level was
found in late postmenopausal controls (>1Oy since
menopause), but it was not statistically significant
(Table IV).
17,B-Oestradiol
The mean value in the breast cancer group did not
differ significantly from that of the control group
(Table II).
Time since mastectomy No statistical difference
was found in the mean oestradiol levels between 17
patients examined close to mastectomy and 7
patients examined years after surgery, or between
each subgroup and the control group (Table III).
Years since menopause No significant difference
was found between normal controls and breast
cancer patients in any of the 3 subgroups, and no
significant difference was found between the 3
subgroups in the control group or in the breast
cancer group (Table IV).
Luteinising hormone (LH)
There was a wide range of variation in both breast
cancer patients and normal controls, and no
significant difference between them (Table II).
Time since mastectomy The mean value in the 9
patients examined years after mastectomy was
higher than in the 19 patients examined 2-12mo
after surgery, but the difference was not statistically
significant (t =2.0). No statistical difference was
found between each subgroup and the control
group (Table III).272 G. SECRETO et al.
Table III Ranges and mean values of testosterone, 17#-oestradiol, luteinising hormone (LH), and prolactin in 19
postmenopausal breast cancer patients examined within 12 months of mastectomy (Group 1) and in 9 patients examined
more than 2 years after surgery (Group 2)
Group 1 Group 2
No. No.
cases Range Mean+s.d. cases Range Mean+s.d. Significance
Testosterone (ngmml) 19 0.19- 0.99 0.58+ 0.2* 9 0.18- 0.76 0.48+ 0.2t NS$
Oestradiol (pgml1) 17 15.50- 40.00 23.67+ 7.3§ 7 15.50- 62.00 25.70+ 16.3§ NS
LH (mIUml-1) 19 28.50-210.00 95.09+43.6§ 9 81.00-200.00 119.15+35.3§ NS
Prolactin (ngmlP) 19 4.60- 17.50 9.04+ 3.5§ 9 5.80- 16.00 8.80+ 3.0§ NS
*Statistical significance vs. normal controls, P<0.001.
tStatistical significance vs. normal controls, P<0.02.
INS, not significant.
§Statistical significane vs. normal controls, not significant.
Table IV Mean values+s.d. of testosterone, 17,B-oestradiol, luteinising hormone (LH), and
prolactin in normal postmenopausal controls and in postmenopausal breast cancer patients
divided into three subgroups according to years since menopause
Breast cancer
Normal controls patients
No. No.
Years since menopause cases Mean+s.d. cases Mean+s.d. Significance
1-5 -
Testosterone (ngmml) 12 0.33+ 0.08 10 0.48+ 0.18* P<O.05
Oestradiol (pgml ') 12 30.37+22.60 10 23.50+ 6.40 NSI
LH (mIUml-') 12 103.00+46.90 10 110.90+34.70 NS
Prolactin (ngml1) 12 8.90+ 6.80 10 8.70+ 2.40 NS
6-10
Testosterone (ngml-1) 11 0.34+ 0.14 8 0.48+ 0.19* NS
Oestradiol (pgml-') 11 24.20+ 6.40 7 29.00+17.10 NS
LH (mIUml-1) 11 100.90+32.80 8 111.90+41.80 NS
Prolactin (ngml1) 11 7.90+ 3.00 8 8.90+ 4.00 NS
>10
Testosterone (ngniP1) 7 0.27+ 0.10 10 0.68+ 0.18 P<0.001
Oestradiol (pgml1) 7 23.30+ 5.40 7 20.60+ 3.90 NS
LH (mIUml-1) 7 70.90+16.20 10 87.40+34.10 NS
Prolactin (ngmlP) 7 5.70+ 1.60 10 9.20+ 3.60 P<0.02
*Statistical significance between 1-5 and >10y since menopause subgroups and between 6-10
and >10y since menopause subgroups, within breast cancer group, P<0.001.
tNS, not significant.
Years since menopause No difference was found in
the 3 subgroups between normal controls and
breast cancer patients, or between the 3 subgroups
within the breast cancer group or within the control
group (Table IV).
Prolactin
The distribution was slightly but not significantly
shifted to higher values in the patient group (Table
II).
Time since mastectomy No difference was found in
the mean prolactin levels between the 19 patients
examined 2-12mo after mastectomy and the 9
patients examined years after surgery, or between
each subgroup and the control group (Table III).
Years since menopause A statistically significant
difference was found between controls and patients
in late postmenopause (> IOy since menopause)
(P<0.02) but not in the other subgroups. No
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subgroups, either within the control group or
within the breast cancer group (Table IV).
Correlations
No correlation was found between the 4 hormones
studied, either in the control group or in the breast
cancer group, considering the overall groups or
dividing them into subgroups according to years
since menopause or, for the patient group,
according to time since mastectomy. A statistically
significant correlation was found between
testosterone and years since menopause (r=0.533,
P<0.01) in breast cancer patients but not in
normal controls. Years since menopause were not
correlated with oestradiol, LH or prolactin levels in
either group. No correlation was found between
any of the 4 hormones studied and age at
menopause in the control group, the breast cancer
group, or their subgroups.
Discussion
The present results show that mean values of serum
oestradiol, LH and prolactin are similar in
postmenopausal women with breast cancer and
normal controls. These findings are in agreement
with most data from the literature for oestradiol
(Bird et al., 1981; Borkowski et al., 1977; England
et al., 1977; Jones et al., 1977; Malarkey et al.,
1977; McFadyen et al., 1976), LH (Bird et al., 1981;
Malarkey et al., 1977; McFadyen et al., 1977) and
prolactin levels (Franks et al., 1974; Jones et al.,
1977; Kwa et al., 1974; Mittra et al., 1974; Sheth et
al., 1975).
In our series, testosterone levels in breast cancer
patients were significantly higher than in normal
controls, considering either the overall groups or
dividing them into subgroups according to years
since menopause or, for the patient group,
according to time since mastectomy.
These data confirm the findings of our previous
papers (Grattarola et al., 1974, 1975), in which
urinary testosterone values higher than normal were
found in postmenopausal breast cancer patients.
Reports of blood testosterone levels in these
patients are few and conflicting (Adami et al., 1979;
Bird et al., 1981; Borkowski et al., 1977; Horn &
Gordan, 1974; Malarkey et al., 1977; McFadyen et
al., 1976). In his review of plasma hormone
concentration in human breast cancer, Zumoff
(1978) pointed out that "in most studies the groups
were heterogeneous, complicated by other diseases
and/or medications, and poorly or not at all
characterized." Our patients were rigidly selected
according to predetermined criteria. In the control
group, testosterone values were in agreement with
E
normal values in most other reports (Adami et al.,
1979; Bird et al., 1981; Malarkey et al., 1977;
Vermeulen, 1976).
Our data have been obtained on the basis of a
single "spot" sample, which has been criticized
(Zumoff, 1978). Diurnal variations of testosterone
in postmenopausal women were shown by
Vermeulen (1976), with highest levels at 8a.m. and
a significant decrease at 8p.m., but the differences
between 8a.m. and 12a.m. were very small. Time
of sampling in our series, both for controls and
breast cancer patients, was between 9a.m. and
11 a.m. We feel it is unlikely that difference in
sampling time can account for the highly significant
difference in testosterone values between the control
group and the breast cancer group, where 50% of
the patients had testosterone levels higher than the
highest testosterone value in the controls.
Furthermore, the correlation of years since
menopause with testosterone but not with the other
hormones is highly suggestive of some abnormality
just in testosterone production and metabolism
rather than for some casual event.
Adipose tissue aromatizes androgens to
oestrogens (Nimrod & Ryan, 1975) and body
weight and the percentage of conversion of
androstenedione to oestrone are highly correlated in
women (Siiteri & MacDonald, 1973). A highly
significant correlation was found -between body
weight and circulating oestrogens in normal
postmenopausal subjects and in patients with
endometrial adenocarcinoma (Frumar et al., 1980;
Judd et al., 1980), but no correlation was present
between body weight and testosterone. Body weight
was recorded in about half of our patients, and it
did not differ from that of the controls.
There is evidence that postmenopausal ovaries
continue to secrete significant amounts of
androgenic hormones (Judd et al., 1974a, 1974b;
Schenker et al., 1979; Vermeulen, 1976), whereas
oestrogens after the menopause are derived almost
completely from the peripheral conversion of
androgens (Grodin et al., 1973). Androgens are
known to be synthesized in the interstitial tissue of
the ovary (Rice & Savard, 1966), and a high
incidence of hyperplastic ovarian interstitial tissue
has been described in breast cancer patients (Smith
& Smith, 1953; Sommers, 1955; Sommers & Teloh,
1952). A previous study from our laboratory
(Grattarola, 1976) showed ovarian interstitial
hyperplasia and elevated urinary testosterone
excretion in a large number of pre- and post-
menopausal breast cancer patients submitted to
ovariectomy.
We can surmise that ovarian interstitial
hyperplasia is more frequent in breast cancer
patients than in normal controls and that the274 G. SECRETO et al.
hyperplastic tissue, under stimulation of elevated
gonadotropin levels, continues to produce larger
and larger amounts of testosterone with the years
since menopause. On the other hand, hormonal
production in normal postmenopausal ovaries is
steady or slightly decreased with years since
menopause.
In conclusion, these data confirm our previous
findings of increased urinary testosterone in breast
cancer patients (Grattarola et al., 1974, 1975), and
further support the hypothesis that
hyperandrogenism may play a role in the
development of breast cancer.
Although our data cannot answer the question
whether the abnormality in testosterone levels is
simply a result of mastectomy itself or whether it
was present preoperatively and indicates a true
metabolic difference between those women destined
to develop breast cancer and those who are not,
we surmise that the latter hypothesis is more
probable. In fact, increased urinary excretion of
testosterone and androstanediol was reported
(Grattarola, 1978) in patients with hyperplastic
alterations of breast epithelium, which is a risk
factor for breast cancer, and we recently found
urinary testosterone and androstanediol excretion
higher than normal in 39% of patients with
hyperplasia and in 61% of patients with cancer of
the breast, examined before mastectomy (Secreto et
al., 1982).
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